地舒单抗 vs 唑来膦酸：肺癌骨转移骨相关事件证据
类型: 支持治疗 / 骨转移 发表日期: 2012-12 入库日期: 2026-05-21 来源: PubMed / Lancet Oncology 标签: 骨转移, 地舒单抗, Denosumab, SRE, 肺癌, 骨保护
Citation
Scagliotti GV, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. Journal of Thoracic Oncology. 2012. PMID: 23154554
Related review/search: NSCLC bone metastases denosumab skeletal-related events
Why it matters for mom
Mom has bone-dominant metastatic disease and is already on denosumab. This evidence supports why bone-protective therapy is not cosmetic: it is meant to reduce skeletal-related events such as fracture, spinal cord compression, surgery, or radiation need.
Practical takeaways
- Continue to monitor calcium, vitamin D, renal function, dental status, and jaw symptoms.
- Denosumab does not replace local treatment if a specific bone lesion threatens structure or causes pain.
- Very low ALP does not rule out active lytic disease.
Questions for doctors
- Is current calcium/vitamin D supplementation adequate with denosumab?
- Does the sternum lesion need orthopedic/radiation evaluation independent of systemic therapy?
- Are there dental procedures planned that require denosumab timing discussion?